TY - JOUR
T1 - Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies
AU - El-Jurdi, Najla
AU - Reljic, Tea
AU - Kumar, Ambuj
AU - Pidala, Joseph
AU - Bazarbachi, Ali
AU - Djulbegovic, Benjamin
AU - Kharfan-Dabaja, Mohamed A.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2013/5
Y1 - 2013/5
N2 - Aims: There is a perceived benefit associated with the administration of donor lymphocyte infusion (DLI) in patients with lymphoid malignancies relapsing after allogeneic hematopoietic cell transplantation. However, it is unclear if and how this benefit varies according to specific diseases. Because administration of DLI is not universally effective and could be associated with significant toxicities resulting in morbidity and mortality, it is imperative to identify cases where benefits outweigh harms of the procedure. Materials & methods: We conducted a systematic review of the published literature and extracted and pooled data independently for each disease cohort: acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). Results: In summary, 39 studies met inclusion criteria. The pooled proportion (95% CI) for complete response was 27% (16-40) in ALL, 55% (15-92) in CLL, 26% (19-33) in MM, 52% (33-71) in NHL and 37% (20-56) in HL. Conclusion: Complete response rates appear higher when DLI is used for relapsed CLL and lymphomas (NHL and HL), and less pronounced in ALL or MM. Absence of data pertaining to disease-specific prognostic determinants, such as adverse genetic or molecular abnormalities, or quantitative disease burden when applicable, limit our ability to identify cases in whom benefits from DLI outweigh risks associated with the procedure within a particular disease.
AB - Aims: There is a perceived benefit associated with the administration of donor lymphocyte infusion (DLI) in patients with lymphoid malignancies relapsing after allogeneic hematopoietic cell transplantation. However, it is unclear if and how this benefit varies according to specific diseases. Because administration of DLI is not universally effective and could be associated with significant toxicities resulting in morbidity and mortality, it is imperative to identify cases where benefits outweigh harms of the procedure. Materials & methods: We conducted a systematic review of the published literature and extracted and pooled data independently for each disease cohort: acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). Results: In summary, 39 studies met inclusion criteria. The pooled proportion (95% CI) for complete response was 27% (16-40) in ALL, 55% (15-92) in CLL, 26% (19-33) in MM, 52% (33-71) in NHL and 37% (20-56) in HL. Conclusion: Complete response rates appear higher when DLI is used for relapsed CLL and lymphomas (NHL and HL), and less pronounced in ALL or MM. Absence of data pertaining to disease-specific prognostic determinants, such as adverse genetic or molecular abnormalities, or quantitative disease burden when applicable, limit our ability to identify cases in whom benefits from DLI outweigh risks associated with the procedure within a particular disease.
KW - DLI
KW - donor lymphocyte infusion
KW - lymphoid malignancies
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=84877282791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877282791&partnerID=8YFLogxK
U2 - 10.2217/imt.13.31
DO - 10.2217/imt.13.31
M3 - Article
C2 - 23638742
AN - SCOPUS:84877282791
SN - 1750-743X
VL - 5
SP - 457
EP - 466
JO - Immunotherapy
JF - Immunotherapy
IS - 5
ER -